Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LEXX

LEXX - Lexaria Bioscience Corp. Stock Price, Fair Value and News

$0.75-0.03 (-3.85%)
Market Closed

24/100

LEXX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

24/100

LEXX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.68

Target 3M

$0.78

Target 6M

$0.72

LEXX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LEXX Price Action

Last 7 days

-6.2%

Last 30 days

33.9%

Last 90 days

-23.5%

Trailing 12 Months

-56.1%

LEXX RSI Chart

LEXX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LEXX Valuation

Market Cap

18.7M

Price/Earnings (Trailing)

-2.03

Price/Sales (Trailing)

26.44

EV/EBITDA

-7.16

Price/Free Cashflow

-2.14

LEXX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.68

Target 3M

$0.78

Target 6M

$0.72

LEXX Fundamentals

LEXX Revenue

Revenue (TTM)

705.9K

Rev. Growth (Yr)

107.14%

LEXX Earnings

Earnings (TTM)

-9.2M

Earnings Growth (Yr)

99.91%

Earnings Growth (Qtr)

99.91%

LEXX Profitability

Operating Margin

96.30%

EBT Margin

-321.80%

Return on Equity

-203.4%

Return on Assets

-152.06%

Free Cashflow Yield

-46.66%

LEXX Investor Care

Shares Dilution (1Y)

41.79%

Diluted EPS (TTM)

-0.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025525.9K615.9K705.9K0
2024404.7K411.0K464.3K496.9K
2023328.6K306.6K226.2K279.8K
2022489.1K372.2K255.4K339.3K
2021650.3K817.9K722.7K605.9K
2020406.7K250.5K252.6K495.9K
2019501.1K628.6K670.9K626.6K
2018183.5K219.3K289.1K325.8K
201748.5K68.6K64.0K113.9K
201667.7K69.8K86.5K45.8K
201543.7K44.8K45.9K62.6K
2014863.1K394.4K159.1K42.5K
20131.5M1.6M1.3M1.1M
20121.1M978.6K1.1M1.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Lexaria Bioscience Corp.

LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and various cannabinoids. The company's DehydraTECH technology evaluates for a variety of therapeutic indications, including hypertension, heart disease, dementia, and diabetes. It is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is based in Kelowna, Canada.
 CEO
 WEBSITEhttps://lexariabioscience.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES7

Lexaria Bioscience Corp. Frequently Asked Questions

LEXX is the stock ticker symbol of Lexaria Bioscience Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Lexaria Bioscience Corp. is 18.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LEXX's fair value in chart for subscribers.

The fair value guage provides a quick view whether LEXX is over valued or under valued. Whether Lexaria Bioscience Corp. is cheap or expensive depends on the assumptions which impact Lexaria Bioscience Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LEXX.

As of Wed Jan 28 2026, LEXX's PE ratio (Price to Earnings) is -2.03 and Price to Sales (PS) ratio is 26.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LEXX PE ratio will change depending on the future growth rate expectations of investors.